Stockreport

Global Registry Data Show Meaningful Overall Survival Benefit in Patients with Advanced Cutaneous T-cell Lymphoma (CTCL) treated with POTELIGEO (mogamulizumab)

KIRIN HLDGS CO LTD S/ADR  (KNBWY) 
US:NASDAQ Investor Relations: kirinholdings.co.jp/english/ir
PDF The PROCLIPI study, one of the largest studies to date in cutaneous T-cell lymphoma (CTCL), is a prospective, observational, multicentre international registry spanning [Read more]